Sanofi-Aventis

Showing 15 posts of 87 posts found.

WHO delists Sanofi-Aventis combo vaccine

August 10, 2010
Manufacturing and Production, Sales and Marketing Sanofi-Aventis, WHO, vaccines

The World Health Organization has dropped a combination vaccine made by Sanofi-Aventis’ subsidiary Shantha Biologics from its list of prequalified …

Sanofi appoints Dr Ian Weatherhead UK coms director

August 4, 2010
Medical Communications, Research and Development, Sales and Marketing Sanofi-Aventis, UK, appointment, research and development, sales and marketing

Sanofi-Aventis UK has appointed Dr Ian Weatherhead as its director of communications. Ian will join the Guildford-based company in October, …

Sanofi’s blockbusters take a hit

July 29, 2010
Sales and Marketing 2010 financials, Genzyme, Q2, Sanofi-Aventis

Generic pressures, European pricing pressures and the impact of the US health reforms combined to dent Sanofi-Aventis’s growth in the …

Genzyme

Genzyme ponders Sanofi offer

July 27, 2010
Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis

Sanofi-Aventis is understood to have approached the board of Genzyme with a takeover bid for the company. News agency Reuters …

Generic Lovenox to dent Sanofi’s earnings

July 26, 2010
Sales and Marketing Lovenox, Sandoz, Sanofi-Aventis, generics

A generic version of Sanofi-Aventis’ blockbuster anti-blood clot treatment Lovenox has just gained approval in the US, signaling a rapid …

US approval for Sanofi’s Jevtana

July 19, 2010
Sales and Marketing Jevtana, Sanofi-Aventis, chemotherapy, prostate cancer

US regulators have approved Sanofi-Aventis’ chemotherapy agent Jevtana in combination with the steroid prednisone to treat men with prostate cancer. …

Pharma manufacturing news in brief

July 6, 2010
Manufacturing and Production BMS, Borregaard Synthesis, Colorcon, JHP Pharma, Saltigo, Sanofi-Aventis, Synthetech, Viropharma, univar

New capital investments from Sanofi-Aventis, Bristol-Myers Squibb, Viropharma and Colorcon head up this round-up of developments in the pharmaceutical manufacturing …

Sanofi licences novel oral anti-diabetic treatment

June 25, 2010
Research and Development, Sales and Marketing Metabolex, Sanofi-Aventis, diabetes

Sanofi-Aventis has signed an exclusive worldwide licensing agreement with US-based diabetes specialist Metabolex for a novel oral anti-diabetic treatment. MBX-2982 …

Sanofi signs microRNA therapy deal

June 23, 2010
Research and Development RNA, Regulus, Sanofi-Aventis

Sanofi-Aventis has entered into a global strategic alliance with US-based therapeutics firm Regulus to develop and commercialise microRNA therapeutics. Regulus …

Sanofi signs biomedical collaboration with MIT

May 27, 2010
Research and Development MIT, Sanofi-Aventis, academia, biomedical

Sanofi-Aventis has formed a strategic alliance with the Centre for Biodmedical Innovation  at the Massachusetts Institute of Technology. The alliance, …

Sanofi signs Indian pain drug development deal

May 5, 2010
Research and Development Glenmark, Sanofi-Aventis, chronic pain, pain therapeutics

Sanofi-Aventis has signed an agreement with Indian firm Glenmark Pharmaceuticals to develop novel agents for the treatment of chronic pain. …

Laurence_Debroux

Sanofi’s chief strategic officer to step down

May 4, 2010
Sales and Marketing Sanofi-Aventis, appointment, sales and marketing

Laurence Debroux, chief strategic officer at Sanofi-Aventis, is to leave the company at the end of June. The company said …

NICE changes its mind on Multaq

March 30, 2010
Sales and Marketing Multaq, NICE, Sanofi-Aventis

NICE has given preliminary approval of Sanofi-Aventis’ Multaq for the management of patients with atrial fibrillation. The decision reverses an …

WHO suspends use of Sanofi-Aventis vaccine

March 18, 2010
Manufacturing and Production Sanofi-Aventis, Shantha Biotechnics, Vaccine

The World Health Organization has temporarily stopped procurement and use of a combination vaccine supplied by Sanofi-Aventis subsidiary Shantha Biotechnics …

Sanofi’s breast cancer candidate tipped for future success

February 25, 2010
Research and Development, Sales and Marketing BSI-201, Sanofi-Aventis, breast cancer

A Sanofi-Aventis drug currently in phase III has been predicted as a future blockbuster in breast cancer treatment. Sanofi’s BSI-201 …

Latest content